Image source: Amgen ... That means the approval of the Repatha Pushtronex system could be a big deal in the future, but right now, this is far from thesis-altering news. The world's biggest ...

Repatha pushtronex The Pushtronex system is an on-body infusor with a prefilled cartridge intended for once-monthly administration. Amgen announced that the Food and Drug Administration (FDA ...

According to the Company, the decision to discontinue the Repatha Pushtronex System was not due to the product’s quality, efficacy or safety. The Repatha Pushtronex System will be discontinued ...

The monthly injection (Repatha Pushtronex system, Amgen) consists of an on-body infusor with a prefilled cartridge of evolocumab (Repatha, Amgen) 420 mg. The single-use device, based on the ...

Amgen (NASDAQ: AMGN) revealed that the Food and Drug Administration (FDA) has approved the Repatha (evolocumab) Pushtronex system, a fresh, monthly single-dose administration option. According to ...

Amgen said the FDA has approved its Repatha (evolocumab) Pushtronex system, the first hands-free, once-monthly delivery option for a PCSK9 inhibitor. Evolocumab is indicated as an adjunct to ...

In the study, about 900 heart disease patients were given a strong statin and monthly shots of either Repatha or a dummy solution. Ultrasound images were taken of an artery with plaque at the ...

Commercializing Amgen's recently approved cholestserol fighter Repatha across the EU hit a ... that list price if NICE approved its proposal. Image source: Amgen. Cutting a better dealThe pushback ...

The Repatha Pushtronex system, an on-body infusor with a prefilled cartridge, is a hands-free device intended to administer 420 mg in a single dose. The approval makes Repatha the first and only ...

Amgen Inc.AMGN0.36%increase; green up pointing triangle on Friday reported widely anticipated data on its new cholesterol-lowering drug Repatha, showing it reduced the risk of deaths, heart ...